Permanent Electrical Disintegration Explained

Permanent Electrical Disintegration Explained

=========================================================================================================

Irreversible Electroporation (IRE) is a revolutionary non-thermal ablation modality that is making waves in the medical field, particularly in cardiology and oncology. This innovative technique uses high-intensity electric fields to create permanent nanopores in cell membranes, triggering apoptosis and permanent cell death without relying on heat.

The mechanism of action involves delivering high-voltage electric pulses through probes inserted into the target tissue. These pulses irreversibly permeabilize cell membranes, leading to loss of cell function and apoptosis. This non-thermal ablation is predictable and minimally inflammatory, causing less pain and faster healing compared to thermal methods like radiofrequency or ultrasound ablation.

Clinical applications of IRE ablation are diverse and promising. In the realm of oncology, the NanoKnife System has been FDA cleared for focal prostate tissue ablation in patients with intermediate-risk prostate cancer. Clinical trials, such as the PRESERVE trial, have shown a 71%-84% negative biopsy rate at 12 months, while preserving urinary and sexual function better than whole-gland therapies.

IRE is also being explored in metabolic surgery adjuncts. Experimental duodenal mucosal ablation (DMA) with IRE in animal models has shown improvements in lipid metabolism and reductions in hepatic fat without major complications, offering a potential minimally invasive treatment for metabolic diseases such as NAFLD.

Moreover, IRE is being investigated in cardiac electrophysiology to selectively ablate myocardial tissue while sparing nerves and muscles, leveraging its tissue selectivity.

In the fight against pancreatic cancer, IRE ablation offers a significant advantage. Unlike conventional surgery and other forms of ultrasound-guided tumor ablation, IRE allows surgeons to access and destroy pancreatic cancer cells with precision. The American Cancer Society estimates that nearly 65,000 Americans will be diagnosed with pancreatic cancer this year, with over 55,000 deaths. However, only about 1/5 of pancreatic cancers are eligible for surgical intervention due to high risk of complications. IRE, with its minimal invasiveness and low risk of complications, could provide a much-needed treatment option for these patients.

The IRE process is called "irreversible" because the damage causes the cell membrane pores to remain open, preventing self-repair. This characteristic also means that IRE isn't subject to heat-sink effects that reduce the efficacy of thermal ablation methods like cryoablation and microwave or radiofrequency ablation.

RBC Medical can help with the development and manufacturing of medical devices for IRE projects. As the 5-year relative survival rate for pancreatic cancer is a mere 9%, the potential of IRE to improve treatment outcomes is undoubtedly exciting. With continued research and development, IRE ablation could become a standard treatment option for a wide range of soft tissue diseases.

References: 1. PRESERVE Trial 2. NanoKnife System 3. Duodenal Mucosal Ablation with Irreversible Electroporation 4. Irreversible Electroporation: A Review of the Technique and Its Clinical Applications 5. NAFLD

1. In the medical field, particularly medtech and medical device design, Irreversible Electroporation (IRE) is a significant development, offering novel ablation therapies and medical-conditions treatments, such as prostate cancer and metabolic diseases.
2. RBC Medical contributes to product development in the medical device industry, working on projects related to IRE, a breakthrough technology that could improve health-and-wellness outcomes for a wide spectrum of patients.
3. IRE, a non-thermal ablation method, is proving to be minimally inflammatory and less painful compared to traditional thermal ablation techniques, like radiofrequency or ultrasound ablation, due to its quality assurance in delivering precise and predictable results.
4. Clinical trials, such as the PRESERVE trial, are investigating the potential benefits of IRE ablation for soft tissue diseases, including prostate cancer and metabolic disorders like NAFLD, with promising results in rigorous science-based research.
5. The medical device known as the NanoKnife System has received FDA clearance for focal prostate tissue ablation in patients with intermediate-risk prostate cancer, demonstrating the technology's viability and potential for wide-scale medical device development.
6. Among various medical conditions, IRE ablation stands out as a potential game-changer for patients diagnosed with pancreatic cancer, offering an alternative minimally invasive treatment option with lower risk of complications compared to conventional interventions.

Read also: